Hostname: page-component-7c8c6479df-8mjnm Total loading time: 0 Render date: 2024-03-27T19:27:25.368Z Has data issue: false hasContentIssue false

Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle

Published online by Cambridge University Press:  20 December 2021

Julia C. Stingl*
Affiliation:
Institute of Clinical Pharmacology, University Hospital of RWTH Aachen, Germany.
Rights & Permissions [Opens in a new window]

Abstract

In the article Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort, Catherine L. Clelland and colleagues for the first time suggest a protective effect of antidepressants against infection with coronavirus disease 2019 (COVID-19) itself. During the observation period of the first wave of the pandemic in New York, more than 50% of patients in the psychiatric hospital studied were infected. From retrospective analysis of the hospital medical records, the authors found a significantly lower risk for infection in patients with antidepressant medication compared to treatment with other psychiatric drugs. The findings of a reduced infection incidence in patients who were already on antidepressant drug therapy underlines a preventive efficacy of antidepressants against COVID-19. Taken together with the prior obtained data of efficacy against deterioration of COVID-19 disease, this study adds a piece of evidence to the positive benefit-risk of antidepressants in repurposing condition against COVID-19.

Type
Editorial
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

Background

In the article Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort, Catherine L. Clelland and colleagues report on the potential protective effect of antidepressants against infection with coronavirus disease 2019 (COVID-19).Reference Clelland, Ramiah, Steinberg and Clelland1 Their retrospective cohort study was conducted in an in-patient setting at a large hospital in New York where it appears reasonable to assume that virus exposure had been relatively uniform across the facility and antidepressant drug intake in patients was common. It adds to the increasing body of knowledge about the potential efficacy of antidepressants against severe courses of SARS-CoV-2 infections, with the finding of a reduced infection incidence in patients who were already on antidepressant drug therapy.

Impact on disease course

Former observational studies had reported a more favourable COVID-19 disease course, such as a reduced risk of intubation or death, in patients treated with serotonin reuptake inhibitors or serotonin-2 antagonist and reuptake inhibitors.Reference Hoertel, Sanchez-Rico, Vernet, Beeker, Jannot and Neuraz2Reference Oskotsky, Maric, Tang, Oskotsky, Wong and Aghaeepour4 A small randomised placebo-controlled trial testing 15 days of fluvoxamine in COVID-19-infected patients found a significant effect on disease deterioration, with no cases of deterioration (0/80) in the fluvoxamine arm compared with 8.3% (6/72) in the placebo arm.Reference Lenze, Mattar, Zorumski, Stevens, Schweiger and Nicol5 Another prospective cohort study with fluvoxamine also showed a preventive effect against deterioration in the patients treated with fluvoxamine.Reference Seftel and Boulware6 In addition, a large randomised multicentre placebo-controlled TOGETHER trial showed significant benefit of fluvoxamine in n = 1472 patients with COVID-19 infection, preventing severe complications.Reference Reis, Dos Santos Moreira-Silva, Silva, Thabane, Milagres and Ferreira7 Another clinical open-label trial with fluvoxamine in n = 51 intensive care unit-treated patients showed a 42% reduction in mortality compared with matched controls.Reference Calusic, Marcec, Luksa, Jurkovic, Kovac and Mihaljevic8

A protective effect against infection

The present study for the first time suggests a protective effect even against the infection itself. During the observation period of the first wave of the pandemic in New York, more than 50% of the patients in the psychiatric hospital of the study were infected. By retrospectively analysing medical records, the authors found significantly lower odds ratios for infection risk in patients taking antidepressant medication compared with other psychiatric drugs.

The potential protective effect was shown over all antidepressant classes, but subgroup analyses showed that especially patients treated with serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors or serotonin-2 antagonist reuptake inhibitors had significantly decreased COVID-19 infections. The association with specific substances of these antidepressant drug classes may be as a result of the relative frequency with which they are prescribed. Indeed, preclinical studies have shown that uptake of SARS-CoV-2 is blocked by all antidepressant drug classes (also tricyclic and tetracyclic).Reference Carpinteiro, Edwards, Hoffmann, Kochs, Gripp and Weigang9

Potential explanation for these findings

As this was a retrospective analysis, the outcomes of infection have not been followed up. However, the findings of not only less severe courses of COVID-19 disease but also of a lower risk for infection support the hypothesis of potential antiviral protective activity provided by the antidepressant drugs analysed in the study. This hypothesis has been advanced by in vitro analyses showing that antidepressants may possess antiviral properties through different mechanisms of action.

First, antidepressants have been shown to interact with the sphingomyelinase/ceramide system, which is likely required to facilitate angiotensin-converting enzyme 2 (ACE2) binding of the SARS-CoV-2 and thereby impair viral host cell entry.Reference Hoertel, Sanchez-Rico, Cougoule, Gulbins, Kornhuber and Carpinteiro10Reference Marin-Corral, Rodriguez-Morato, Gomez-Gomez, Pascual-Guardia, Munoz-Bermudez and Salazar-Degracia12 In addition to antidepressant drugs, several medications share the property of functional inhibition of the acid sphingomyelinase. Recent observational data show a reduced likelihood of intubation or death in (n = 2846) COVID-19-infected patients who are treated with any of the functional sphingomyelinase/ceramide system inhibitory drugs.Reference Hoertel, Sanchez-Rico, Gulbins, Kornhuber, Carpinteiro and Lenze13

Second, antidepressants may exert anti-inflammatory activity, by reducing levels of proinflammatory cytokines including interleukin (IL-6), IL-10, tumour necrosis factor (TNF)-alpha, and chemokine (C-C motif) ligand (CCL)-2 or by activating the sigma-1 receptor.Reference Ishima, Fujita and Hashimoto14Reference Roumestan, Michel, Bichon, Portet, Detoc and Henriquet17

Third, serotonin uptake inhibitors may reduce platelet activity by decreasing serotonin levels in platelets. This may positively affect the course of COVID-19 disease and counteract the serotonin syndrome that seems to occur in some of these patients.Reference Sukhatme, Reiersen, Vayttaden and Sukhatme18

In addition to the pharmacological properties of the antidepressant drugs, people with depression tend to avoid social contacts. During the pandemic, depression-induced social isolation may have prevented viral exposure and COVID illness. However, there was no difference in COVID-19 infection status between patients with manic and depressive symptoms in the study by Clelland. Hence, confounding by indication for the medication appears unlikely.

Conclusions

In the presence of already substantial evidence for an association of antidepressant drug use with better outcomes in patients with a severe and laboratory-confirmed COVID-19 infection, this study highlights the potentially underestimated finding of a protective effect of antidepressant drug use (such as the selective serotonin reuptake inhibitor fluoxetine or the serotonin-2 antagonist and reuptake inhibitor trazodone) against the infection itself in patients who are being treated with antidepressants for depression and/or other psychiatric disorders. This is especially worth mentioning because antidepressant drug use is common in a substantial proportion of the general population. It is possible that the inclusion of severe cases in epidemiological studies (i.e. only patients with laboratory-confirmed COVID-19 infection) may contribute to this underestimation. Taken together with the prior evidence, this study underlines the benefit of using antidepressant drugs to prevent COVID-19 infection and deterioration of COVID-19 disease.

Taken together with the prior evidence, this study underlines the benefit of using certain antidepressant drugs, such as the selective serotonin reuptake inhibitor fluoxetine or the serotonin-2 antagonist and reuptake inhibitor trazodone, to prevent COVID -19 infection and deterioration of COVID-19 disease.

Declaration of interest

J.C.S. is an editorial board member in the BJPsych Open.

References

Clelland, C, Ramiah, K, Steinberg, L, Clelland, J. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open 2021; 8: E6.CrossRefGoogle Scholar
Hoertel, N, Sanchez-Rico, M, Vernet, R, Beeker, N, Jannot, AS, Neuraz, A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry 2021; 26: 5199–212.CrossRefGoogle ScholarPubMed
Diez-Quevedo, C, Iglesias-Gonzalez, M, Giralt-Lopez, M, Rangil, T, Sanagustin, D, Moreira, M, et al. Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients. Acta Psychiatr Scand 2021; 143 526–34.CrossRefGoogle ScholarPubMed
Oskotsky, T, Maric, I, Tang, A, Oskotsky, B, Wong, RJ, Aghaeepour, N, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open 2021; 4: e2133090.CrossRefGoogle ScholarPubMed
Lenze, EJ, Mattar, C, Zorumski, CF, Stevens, A, Schweiger, J, Nicol, GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020; 324: 2292–300.CrossRefGoogle ScholarPubMed
Seftel, D, Boulware, DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis 2021; 8: ofab050.CrossRefGoogle Scholar
Reis, G, Dos Santos Moreira-Silva, EA, Silva, DCM, Thabane, L, Milagres, AC, Ferreira, TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health [Epub ahead of print] 27 Oct 2021. Available from: https://doi.org/10.1016/S2214-109X(21)00448-4.Google ScholarPubMed
Calusic, M, Marcec, R, Luksa, L, Jurkovic, I, Kovac, N, Mihaljevic, S, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol [Epub ahead of print] 1 Nov 2021. Available from: https://doi.org/10.1111/bcp.15126.CrossRefGoogle ScholarPubMed
Carpinteiro, A, Edwards, MJ, Hoffmann, M, Kochs, G, Gripp, B, Weigang, S, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med 2020; 1: 100142.CrossRefGoogle ScholarPubMed
Hoertel, N, Sanchez-Rico, M, Cougoule, C, Gulbins, E, Kornhuber, J, Carpinteiro, A, et al. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry [Epub ahead of print] 2 Aug 2021. Available from: https://doi.org/10.1038/s41380-021-01254-3.CrossRefGoogle ScholarPubMed
Kornhuber, J, Hoertel, N, Gulbins, E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry [Epub ahead of print] 4 Oct 2021. Available from: https://doi.org/10.1038/s41380-021-01309-5.CrossRefGoogle ScholarPubMed
Marin-Corral, J, Rodriguez-Morato, J, Gomez-Gomez, A, Pascual-Guardia, S, Munoz-Bermudez, R, Salazar-Degracia, A, et al. Metabolic signatures associated with severity in hospitalized COVID-19 patients. Int J Mol Sci 2021; 22; 4794.Google Scholar
Hoertel, N, Sanchez-Rico, M, Gulbins, E, Kornhuber, J, Carpinteiro, A, Lenze, EJ, et al. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study. Clin Pharmacol Ther 2021; 110: 1498–511.CrossRefGoogle ScholarPubMed
Ishima, T, Fujita, Y, Hashimoto, K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 2014; 727: 167–73.CrossRefGoogle ScholarPubMed
Rosen, DA, Seki, SM, Fernandez-Castaneda, A, Beiter, RM, Eccles, JD, Woodfolk, JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 2019; 11; eaau5266.Google Scholar
Kohler, CA, Freitas, TH, Stubbs, B, Maes, M, Solmi, M, Veronese, N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol 2018; 55: 4195–206.Google ScholarPubMed
Roumestan, C, Michel, A, Bichon, F, Portet, K, Detoc, M, Henriquet, C, et al. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res 2007; 8: 35.CrossRefGoogle ScholarPubMed
Sukhatme, VP, Reiersen, AM, Vayttaden, SJ, Sukhatme, VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol 2021; 12: 652688.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.